VIKING THERAPEUTICS INC (VKTX) Stock Overview
USA - NASDAQ:VKTX - US92686J1060 - Common Stock
VKTX Key Statistics, Chart & Performance
The current stock price of VKTX is 31.42 USD. In the past month the price increased by 17.99%. In the past year, price decreased by -59.73%.
VKTX Latest News, Press Relases and Analysis
VKTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.59 | 403.98B | ||
| AMGN | AMGEN INC | 13.57 | 159.34B | ||
| GILD | GILEAD SCIENCES INC | 15.69 | 150.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 109.33B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.94B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.98B | ||
| ARGX | ARGENX SE - ADR | 88.4 | 50.13B | ||
| INSM | INSMED INC | N/A | 33.90B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.06 | 34.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.54B | ||
| NTRA | NATERA INC | N/A | 25.81B | ||
| BIIB | BIOGEN INC | 9.23 | 21.66B |
Related stock screener links
About VKTX
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 48 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Company Info
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA 92130 US
CEO: Brian Lian
Employees: 48
Phone: 18587044660
VIKING THERAPEUTICS INC / VKTX FAQ
What is the stock price of VIKING THERAPEUTICS INC today?
The current stock price of VKTX is 31.42 USD. The price decreased by -4.73% in the last trading session.
What is the ticker symbol for VIKING THERAPEUTICS INC stock?
The exchange symbol of VIKING THERAPEUTICS INC is VKTX and it is listed on the Nasdaq exchange.
On which exchange is VKTX stock listed?
VKTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VIKING THERAPEUTICS INC stock?
23 analysts have analysed VKTX and the average price target is 95.81 USD. This implies a price increase of 204.94% is expected in the next year compared to the current price of 31.42. Check the VIKING THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIKING THERAPEUTICS INC worth?
VIKING THERAPEUTICS INC (VKTX) has a market capitalization of 3.53B USD. This makes VKTX a Mid Cap stock.
How many employees does VIKING THERAPEUTICS INC have?
VIKING THERAPEUTICS INC (VKTX) currently has 48 employees.
What are the support and resistance levels for VIKING THERAPEUTICS INC (VKTX) stock?
VIKING THERAPEUTICS INC (VKTX) has a support level at 31.41 and a resistance level at 33.57. Check the full technical report for a detailed analysis of VKTX support and resistance levels.
Should I buy VIKING THERAPEUTICS INC (VKTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VKTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VKTX, evaluating the profitability, health, valuation and growth aspects
- VIKING THERAPEUTICS INC (VKTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIKING THERAPEUTICS INC (VKTX) Sales and EPS estimates to see what analysts future expectations are.
- VIKING THERAPEUTICS INC (VKTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIKING THERAPEUTICS INC (VKTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIKING THERAPEUTICS INC (VKTX) Stock Chart to make your own analysis
- VIKING THERAPEUTICS INC (VKTX) Latest news and press-releases to stay up to date.
Does VIKING THERAPEUTICS INC (VKTX) stock pay dividends?
VKTX does not pay a dividend.
When does VIKING THERAPEUTICS INC (VKTX) report earnings?
VIKING THERAPEUTICS INC (VKTX) will report earnings on 2025-10-22, after the market close.
What is the Price/Earnings (PE) ratio of VIKING THERAPEUTICS INC (VKTX)?
VIKING THERAPEUTICS INC (VKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of VIKING THERAPEUTICS INC (VKTX) stock?
The outstanding short interest for VIKING THERAPEUTICS INC (VKTX) is 24.63% of its float. Check the ownership tab for more information on the VKTX short interest.
VKTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to VKTX. When comparing the yearly performance of all stocks, VKTX is a bad performer in the overall market: 93.29% of all stocks are doing better.
VKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VKTX. VKTX has a great financial health rating, but its profitability evaluates not so good.
VKTX Financial Highlights
Over the last trailing twelve months VKTX reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -62.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.72% | ||
| ROE | -21.57% | ||
| Debt/Equity | 0 |
VKTX Forecast & Estimates
23 analysts have analysed VKTX and the average price target is 95.81 USD. This implies a price increase of 204.94% is expected in the next year compared to the current price of 31.42.